Haystack Oncology and Longeviti Neuro Solutions, life science companies affiliated with Johns Hopkins University, have signed leases at City Garage Science and Technology Center totaling over 30,000 square feet in Baltimore Peninsula. Additionally, Launchport has expanded their operations by 6,200-sf.
Haystack Oncology Launches with $56 Million in Series A Financing to Accelerate Adoption of Post-Op Cancer Detection Technology and Optimize Cancer Therapy Monitoring and Treatment
Haystack Oncology (“Haystack”), an oncology company that applies the next generation of circulating tumor DNA (ctDNA) detection technology to optimize minimal residual disease (MRD) testing and better inform decisions around therapy, today announced that it raised $56 million in Series A financing. The funding will be used for the continued development and planned 2023 commercialization of its best-in-class personalized cancer diagnostic test that can detect as few as one mutant molecule in a million DNA molecules, positioning it as the most sensitive ctDNA-based MRD test for use in solid tumors. The financing was led by Catalio Capital Management (“Catalio”), which co-founded Haystack through its private equity and structured equity investment vehicles. Additional investors include Bruker, Exact Ventures, the venture arm of Exact Sciences and Alexandria Venture Investments.